Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Boehringer Ingelheim Expands Alliance with Graffinity

  • Boehringer Ingelheim Pharmaceuticals chose to exercise options in its original agreement with Graffinity Pharmaceuticals  that will increase the number of targets screened by Graffinity as part of this global alliance. Under the terms of the agreement, Graffinity will receive additional technology access fees for the generation of multiple novel small molecule hit series against a variety of drug targets from different therapeutic areas.

    Graffinity will apply its fragment-based drug discovery technology and drug fragment chemical microarrays to identify small molecule hit structures focusing on compounds with novel modes of action. Financial details of the transaction were not disclosed.

    Both companies reiterated the importance of the continuation and expansion of this successful collaboration which complements Boehringer Ingelheim's in-house capabilities and will include a significant number of additional drug targets.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »